Delcath Systems (NASDAQ:DCTH) Earns "Overweight" Rating from Stephens

Stephens reissued their overweight rating on shares of Delcath Systems (NASDAQ:DCTH - Free Report) in a report released on Monday,Benzinga reports. The firm currently has a $25.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reiterated a "buy" rating and set a $29.00 price objective (up from $24.00) on shares of Delcath Systems in a research report on Friday, May 23rd. Wall Street Zen downgraded Delcath Systems from a "strong-buy" rating to a "buy" rating in a report on Sunday, June 1st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $24.00.

Delcath Systems Stock Up 0.8%

DCTH traded up $0.11 during midday trading on Monday, hitting $14.05. 430,340 shares of the company were exchanged, compared to its average volume of 396,385. The firm's 50 day moving average price is $14.56 and its 200-day moving average price is $13.74. Delcath Systems has a 1-year low of $7.17 and a 1-year high of $18.23. The firm has a market capitalization of $489.36 million, a P/E ratio of -28.10 and a beta of 0.95.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). The company had revenue of $19.80 million during the quarter, compared to analyst estimates of $16.83 million. Delcath Systems had a negative return on equity of 29.44% and a negative net margin of 26.38%. On average, sell-side analysts predict that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of Delcath Systems

Several hedge funds have recently modified their holdings of the stock. Jefferies Financial Group Inc. acquired a new stake in Delcath Systems in the fourth quarter worth $251,000. Principal Financial Group Inc. boosted its position in shares of Delcath Systems by 28.8% during the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock worth $1,387,000 after purchasing an additional 25,736 shares in the last quarter. Private Advisor Group LLC acquired a new stake in shares of Delcath Systems in the 4th quarter valued at about $153,000. Jane Street Group LLC grew its stake in shares of Delcath Systems by 1,364.6% in the 4th quarter. Jane Street Group LLC now owns 178,797 shares of the company's stock valued at $2,153,000 after buying an additional 166,589 shares during the period. Finally, Bank of America Corp DE increased its position in Delcath Systems by 1,816.5% in the 4th quarter. Bank of America Corp DE now owns 25,700 shares of the company's stock valued at $309,000 after buying an additional 24,359 shares in the last quarter. Institutional investors own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.